Is Adaptive Biotechnologies Stock Halal?

Is Adaptive Biotechnologies Stock Halal?

How much of Adaptive Biotechnologies’ revenue comes from haram?

Adaptive Biotechnologies develops immune medicine platforms used to diagnose and treat diseases such as cancer, autoimmune conditions, and infectious diseases.

Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

Adaptive Biotechnologies earns its revenue from the following revenue sources:

  • Sequencing Revenue:

Includes revenue generated from providing sequencing services and testing through clonoSEQ and immunoSEQ products and services to clinical and research customers, respectively.

  • Development Revenue:

Includes revenue generated from regulatory or development services provided to biopharmaceutical customers to support therapeutic development activities.

The contributions from each of Adaptive Biotechnologies’ revenue segments in their Q2 2021 report were as follows:

Practical Islamic Finance concludes:

None of Adaptive Biotechnologies’ revenue comes from anything inherently haram.

Does Adaptive Biotechnologies rely on interest to operate?

[wbcr_php_snippet id=”11367″]

What are Adaptive Biotechnologies Environmental, Social and Governance (ESG) Impact?


No notable environmental highlights. 


Adaptive Biotechnologies has a relatively high Glassdoor rating of 3.8 out of 5 from current and previous employees compared to a 3.3 average for all other Glassdoor rated companies. 


No notable governance highlights.

Practical Islamic Finance concludes: 

Adaptive Biotechnologies have a net positive ESG impact. 

Comfort Rating 

From Adaptive Biotechnologies’ business, financial, and ESG reviews, Practical Islamic Finance rates Adaptive Biotechnologies stock as: 

Comfortable to invest in from a halal perspective.


Adaptive Biotechnologies 2020 Annual Report

Adaptive Biotechnologies Q2 2021 Report 

Adaptive Biotechnologies Reviews 

Subscribe to get our “Intro to Halal-Conscious Investing” and much more for FREE!

Enter your email address to subscribe:*